



# EMERGENT®

We deliver peace of mind in an uncertain world

## FACT SHEET

JANUARY 2024

**12**

Marketed Products

### Molecule-to-Market **BIOSERVICES**

Development Services  
Drug Substance  
Drug Product  
Packaging

**1.12B**

2022 Total Revenue

**1,600**

Employees



At Emergent, our mission is to **protect and enhance life.**

We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For nearly 25 years, we've been at work defending people from things we hope will never happen—so that we're prepared, just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails.



### PRODUCT PORTFOLIO\*

#### GOVERNMENT/MEDICAL COUNTERMEASURES

<b>BioThrax®</b> (Anthrax Vaccine Absorbed)	<b>CYFENDUS®</b> (Anthrax Vaccine Adsorbed, Adjuvanted)	<b>Anthrasil®</b> (Anthrax Immune Globulin Intravenous (Human))	<b>raxibacumab Injection</b> A fully human monoclonal antibody	<b>ACAM2000®</b> (Smallpox (Vaccinia) Vaccine, Live)	<b>VIGIV CNJ-016®</b> (Vaccinia Immune Globulin Intravenous (Human))
<b>BAT®</b> (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine))	<b>Ebanga™</b> (ansuvimab-zykl)	<b>RSDL®</b> (Reactive Skin Decontamination Lotion Kit)	<b>TEMBEXA®</b> (brincidofovir)	<b>Trobigard Auto-injector® **,1</b> (Atropine sulfate/obidoxime chloride auto-injector)	

#### COMMERCIAL

**NARCAN® Nasal Spray**  
(Naloxone HCl)

\* Products approved by U.S. FDA. Approvals vary by country.

\*\* These product candidates have not been approved by the U.S. FDA or any other regulatory authority.



### DEVELOPMENT AND MANUFACTURING EXPERTISE

#### EMERGENT BIOSERVICES

Molecule-to-market services across entire drug development life cycle from clinical through commercial supply



## OUR SCIENCE & DEVELOPMENT PROGRAMS \*\*, 2

<b>UniFlu</b> (Universal influenza vaccine)	NA	PHASE 1	INFECTIOUS DISEASE
<b>WEVEE VLP</b> (Western, Eastern and Venezuelan equine encephalitic VLP vaccine)	NA	PHASE 1	INFECTIOUS DISEASE
<b>EBS-Lassa</b> (rVSV-vectored vaccine for Lassa fever) <sup>3</sup>	CEPI	PHASE 1	INFECTIOUS DISEASE
<b>EBS-Marburg</b> (rVSV-vectored vaccine for Marburg virus disease) <sup>3</sup>	NIAID/AURO VACCINES	PRECLINICAL	INFECTIOUS DISEASE
<b>EBS-Sudan</b> (rVSV-vectored vaccine for Sudan virus disease) <sup>3</sup>	NIAID/AURO VACCINES	PRECLINICAL	INFECTIOUS DISEASE
<b>Pan-Ebola mAb</b> (Ebola/Sudan monoclonal)	IBT	PRECLINICAL	INFECTIOUS DISEASE
<b>CGRD-001</b> (Pralidoxime chloride/atropine auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
<b>EGRD-001</b> (Diazepam auto-injector)	DoD	DEVELOPMENT	NERVE AGENT ANTIDOTE
<b>SIAN</b> (Stabilized isoamyl nitrite)	BARDA/SwRI	PHASE 1	CHEMICAL AGENT ANTIDOTE

### CORPORATE OFFICE

- Gaithersburg, Maryland

### CORPORATE AFFAIRS

- Washington, DC

### DEVELOPMENT SERVICES

- Gaithersburg, Maryland

### SCIENCE & DEVELOPMENT

- Dublin, Ireland
- Gaithersburg, Maryland
- Winnipeg, Canada

### MANUFACTURING

- Baltimore, Maryland (Bayview)
- Baltimore, Maryland (Camden)
- Canton, Massachusetts
- Hattiesburg, Mississippi
- Lansing, Michigan
- Rockville, Maryland
- Winnipeg, Canada

### SALES & MARKETING

- Gaithersburg, Maryland
- London, UK
- Philadelphia, Pennsylvania
- Toronto, Canada

### CONTACT INFORMATION

#### Corporate Office

300 Professional Drive  
Gaithersburg, MD 20879 USA  
240.631.3200

#### Investor Inquiries

Richard Lindahl  
EVP and Chief Financial Officer  
240.631.3360  
lindahlr@ebsi.com

#### Bioservices Inquiries

Brooke Marshall  
Director, Sales & BD  
800.441.4225  
cdmo@ebsi.com

#### Media Inquiries

Assal Hellmer  
Vice President, Communications  
mediarelations@ebsi.com

BARDA - Biomedical Advanced Research and Development Authority  
CEPI - Coalition for Epidemic Preparedness Innovations  
DoD - U.S. Department of Defense  
IBT - Integrated BioTherapeutics  
NIAID - National Institute of Allergy and Infectious Diseases  
SwRI - Southwest Research Institute  
USAMMDA - U.S. Army Medical Materiel Development Activity

1 Trobigrad is not approved by the FDA and is procured by authorized government agencies under special circumstances  
2 Status reflects both clinical and nonclinical development under the FDA Animal Efficacy Rule.  
3 rVSV - recombinant Vesicular Stomatitis Virus

# EMERGENT<sup>®</sup>

Learn more at

[emergentbiosolutions.com](https://www.emergentbiosolutions.com)



Emergent BioSolutions®, ACAM2000®, Anthrasil®, BAT®, BioThrax®, Cyfendus™, RSDL®, NARCAN®, CNJ-016®, Trobigrad®, TEMBEXA® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. Ebanga™ is a trademark of Ridgeback Biotherapeutics LP. All rights reserved.  
07/30/2023 PP-CORP-ALL-00001

#### Safe Harbor Statement



This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, our future goals and growth strategy, total contract value, the timing and results of clinical trials, development-stage programs and regulatory approvals, the intended results of our platforms and technologies, the timing of future deliverables, expansion into new global markets, and any other statements containing the words "will," "believes," "expects," "anticipates," "intends" "plans," "targets," "forecasts," "estimates" and similar expressions. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of publication, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary language as well as the information identified under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.